Moberg Pharma´s Interim report January - June 2023 : vi

Moberg Pharma´s Interim report January - June 2023MOB-015 IS RECOMMENDED FOR APPROVAL IN 13 EUROPEAN COUNTRIES SIX-MONTH PERIOD (JAN-JUN 2023)·      EBITDA SEK -10.7 million (-9.1)·      Operating profit (EBIT) SEK -12.0 million (-10.4)&middo...

Related Keywords

United States , Ireland , Sweden , American , Moberg Pharma , Anna Ljung , European Union , Decentralized Procedure , North American , Annual General Meeting ,